Affiliations: Unité de Recherches, d’Hémorhéologie Clinique de Bourgogne, Centre de Diabétologie et des Maladies de la Nutrition, Centre Hospitalier de Nevers, 58320 Pougues les Eaux, France
Correspondence:
[*]
Correspondence to C. Le Dévéhat.
Note: [] Accepted by: Editor A.M. Ehrly
Abstract: Numerous studies have shown the importance of blood rheological abnormalities in the course of venous insufficiency or thrombogenesis. Hemorheological interest in Troxerutin is now better known but the actual data and results are still fragmented. To confirm the clinical interest in the use of Troxerutin, it is necessary to show that the informations concerning its rheological action in vitro also confirm themselves in vivo. This study, in a double blind test with placebo, was carried out on 40 subjects: 20 control subjects and 20 patients suffering from varicose vein disease of which 10 received 4 g of Troxerutin per day for 15 days, 10 received a placebo. Before and after treatment, the following microrheological parameters were measured in an antecubital vein and in varicose veins of the legs, before and after a stasis of 30 minutes: hematocrit, fibrinogen, plasma viscosity, whole blood filterability, erythrocyte filterability and erythrocyte aggregation tendency. A significant improvement of the main microrheological parameters of blood viscosity and in particular of the erythrocyte aggregation tendency after stasis confirms the therapeutic interest in Troxerutin in venous pathology or vascular stasis.
